

9F, No. 108, Jhouzih St.,Taipei, Taiwan Tel: + 886-2-8751-1888 Fax: + 886-2-6602-1218 E-mail: sales@abnova.com

Datasheet

PSMB4 monoclonal antibody (M01), clone 6G7-E8

Catalog Number: H00005692-M01

Regulatory Status: For research use only (RUO)

Product Description: Mouse monoclonal antibody raised against a full length recombinant PSMB4.

Clone Name: 6G7-E8

Immunogen: PSMB4 (AAH00331, 1 a.a. ~ 264 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Sequence:

MEAFLGSRSGLWAGGPAPGQFYRIPSTPDSFMDPAS ALYRGPITRTQNPMVTGTSVLGVKFEGGVVIAADMLG SYGSLARFRNISRIMRVNNSTMLGASGDYADFQYLKQ VLGQMVIDEELLGDGHSYSPRAIHSWLTRAMYSRRSK MNPLWNTMVIGGYADGESFLGYVDMLGVAYEAPSLA TGYGAYLAQPLLREVLEKQPVLSQTEARDLVERCMRV LYYRDARSYNRFQTATVTEKGVEIEGPLSTETNWDIAH MISGFE

Host: Mouse

Reactivity: Human

Applications: ELISA, IHC-P, S-ELISA, WB-Re (See our web site product page for detailed applications information)

Protocols: See our web site at http://www.abnova.com/support/protocols.asp or product page for detailed protocols

Isotype: IgG1 kappa

Storage Buffer: In 1x PBS, pH 7.4

Storage Instruction: Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Entrez GenelD: 5692

Gene Symbol: PSMB4

Gene Alias: HN3, HsN3, PROS26

Gene Summary: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. [provided by RefSeq]

References:

1. Predictive value of PAK6 and PSMB4 expression in patients with localized prostate cancer treated with dose-escalation radiation therapy and androgen deprivation therapy. Zapatero A, Morente M, Nieto S, Martin de Vidales C, Lopez C, Adrados M, Arellano R, Artiga MJ, Garcia-Vicente F, Herranz LM, Leaman O. Urol Oncol. 2014 Jun 16. pii: S1078-1439(14)00167-7.